For the last several quarters, Gilead Sciences’ earnings calls have been colored by anticipation for the launch of the California drugmaker's long-acting HIV pre-exposure prophylaxis (PrEP) option. | ...

Total product sales -- $7.3 billion in fiscal Q3 2025, up 4% sequentially from Q2 2025, with growth driven by the HIV ...

Biotech bigwig Gilead Sciences, Inc. GILD is scheduled to report third-quarter 2025 result s on Oct. 30, after market close.

HIV prevention drug Lenacapavir, which has been tested in South Africa during clinical trials, will be made available in the country in 2026 for high-risk groups.

Introduction HIV pre-exposure prophylaxis (PrEP) is an effective HIV prevention tool, reducing infection risk by up to 99% when used as prescribed. Despite its proven efficacy, PrEP uptake remains ...

Elizabeth M. Stone ([email protected]), Rutgers University, New Brunswick, New Jersey. Nicholas J. Seewald, University of Pennsylvania, Philadelphia, Pennsylvania ...

ZURICH, Oct 8 (Reuters) - UBS (UBSG.S), opens new tab said on Wednesday it was examining the impact of the bankruptcy of First Brands on several of its investment funds, with the Swiss bank exposed to ...

While human cases of rabies in the United States are rare, it’s still a deadly disease: six people have died from rabies nationwide since September 2024, a US Centers for Disease Control and ...

Arlington, VA –The Centers for Disease Control and Prevention (CDC), on behalf of the U.S. Public Health Service (PHS), has released the 2025 Guidelines for the Management of Occupational Exposure to ...

A Prescription Drug User Fee Act target date of June 16, 2026 has been set for the application. The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for ...

HIV Virus Creative artwork featuring colorized 3D prints of HIV virus particles. The virus surface (red) is covered with proteins (dark blue) that enable the virus to enter and infect human cells, and ...